Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.42 |
| ▸ | LPL | P06858 | 9/20 | 0.42 |
| ▸ | F11 | P03951 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17893865 | 1.00 | LIPG (0.42) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL17894260 | 1.00 | LIPG (0.42) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL17903578 | 0.92 | LIPG (0.42) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL17903587 | 0.90 | LPL (0.44) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL17903574 | 0.90 | LIPG (0.40) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL17903435 | 0.89 | LIPG (0.44) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL1129310 | 0.86 | LIPG (0.48) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL20110052 | 0.85 | LPL (0.40) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL19652465 | 0.85 | LIPG (0.43) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL19652467 | 0.85 | LIPG (0.43) | LIPGLPLF11F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240543-B1 | BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| EP-3240546-B1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2020-10-21 | — | — | EP | disclosed |
| US-10208047-B2 | Tertiary alcohol imidazopyrazine BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208047-B2 | Tertiary alcohol imidazopyrazine BTK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180118766-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118766-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170342076-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342076-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3240546-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3240543-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109216-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109222-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109216-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016109222-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016106628-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| WO-2016106624-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208047-B2 | Tertiary alcohol imidazopyrazine BTK inhibitors | BTK, SYK, ABL1 | LIPG 1648/4885LPL 2325/4885F11 775/4885 |
| US-20180118766-A1 | BTK INHIBITORS | BTK, SYK, LYN | LIPG 1114/4885LPL 2228/4885F11 1015/4885 |
| US-20170342076-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | BTK, SYK, ABL1 | LIPG 1648/4885LPL 2325/4885F11 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.